Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Commissioner Sees Industry Role In Regulatory Science Initiative

This article was originally published in The Tan Sheet

Executive Summary

Drug and device firms should have a seat at the table as FDA strengthens its regulatory science program and thus speeds pre-market product reviews, Commissioner Margaret Hamburg says

You may also be interested in...



FDA Strategic Documents Outline Regulatory Science Priorities

Improving regulatory tools and scientific know-how are among FDA's top priorities over the next five years, according to a draft strategic report

Calif. nixes smoking-cessation bill

Gov. Arnold Schwarzenegger vetoes a bill that would have mandated unprecedented insurance coverage for smoking-cessation products and services in California. Senate Bill 220 cleared the state Senate in August by a 22-13 margin and was vetoed Sept. 30. "This bill represents a costly health mandate that goes beyond current federal law," Schwarzenegger wrote of SB 220, which would have required coverage of Rx and OTC cessation drugs with no copayments, coinsurance or deductibles (1"The Tan Sheet" July 12, 2010). Although the bill's proponents touted it as a means of cutting into California's $8.6 billion annual costs related to tobacco addiction, the governor signed other legislation to codify broader preventive health service coverage requirements. A spokeswoman for the American Lung Association said the group is "very disappointed" in California's failure to pass SB 220, and it will await the results of the state's upcoming gubernatorial election before setting out a plan for reintroducing the bill in 2011

FDA Strategic Documents Outline Regulatory Science Priorities

Improving regulatory tools and scientific know-how are among FDA's top priorities over the next five years, according to a draft strategic report

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel